Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2016', provides in depth analysis on Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted pipeline therapeutics. The report provides comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects - The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Overview 6 Therapeutics Development 7 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Stage of Development 7 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Therapy Area 8 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Indication 9 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Products Glance 10 Early Stage Products 10 Unknown Stage Products 11 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Companies 12 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Products under Development by Universities/Institutes 14 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 20 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development 21 Addex Therapeutics Ltd 21 Prexton Therapeutics SA 22 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles 23 ADX-88178 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 JBPOS-0101 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PXT-2331 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 VU-0418506 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Projects 30 Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Featured News & Press Releases 31 Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction 31 Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial 31 Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases 32 Mar 07, 2016: Parkinsons disease: Prexton Therapeutics starts phase 1 clinical trial 32 Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis 33 Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases 34 Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases 35 Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model 35 Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson's Disease In Journal Of Pharmacology And Experimental Therapeutics 36 Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinsons Disease 37 Feb 25, 2008: Addex in Collaboration with Merck & Co., Inc. Achieves First Milestone in Parkinson's disease 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Comparative Analysis by Unknown Stage Development, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Addex Therapeutics Ltd, H2 2016 21 Pipeline by Prexton Therapeutics SA, H2 2016 22 Dormant Projects, H2 2016 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
